MLH1 and MSH2 expression in pterygia

被引:7
|
作者
Schneider, Barbara G.
Sahni, Deshdeepak
Torres, Juan C.
Dushku, Nicholas
Reid, Ted W.
机构
[1] Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA
[2] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[3] Louisiana State Univ, Hlth Sci Ctr, New Orleans, LA USA
[4] Kaiser Permanente Med Ctr, Sacramento, CA USA
[5] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA
关键词
pterygium; loss of heterozygosity; microsatellite instability; mismatch repair;
D O I
10.1097/ICO.0b013e3180316c76
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: Pterygia have been reported to share some of the genetic defects seen in cancers, including microsatellite instability (MSI). We examined pterygia for the presence of proteins typically missing or defective in adenocarcinomas with MSI. We also performed microsatellite analysis on DNA from pterygia to test for instability in the size of the microsatellites, using markers conventionally used to characterize MSI in tumors (Bethesda convention markers). Methods: We examined 13 pterygia by immunohistochemistry for MLH1 and MSH2, 2 proteins involved in DNA mismatch repair. In addition, we amplified the pterygial DNA with primers specific for 5 Bethesda markers (BAT25, BAT26, D2S123, D5S346, and D17S250). Results: MLH1 staining was present at low levels in the basal cells of the cornea and migrating limbal cells of the pterygia. MSH2 staining was present in basal and in maturing epithelial cells of the cornea and migrating limbal cells of pterygia. We observed no reproducible examples of MSI or loss of heterozygosity (LOH). Conclusions: We were unable to confirm the presence of MSI and LOH by using the markers we examined. MSH2 staining appeared to be normal in pterygia. MLH1 staining was present but in reduced amounts compared with that seen in the conjunctiva.
引用
收藏
页码:468 / 472
页数:5
相关论文
共 50 条
  • [11] Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine
    Schulmann, K
    Hahn, SA
    Brasch, F
    Schmiegel, W
    [J]. CANCER, 2003, 98 (08) : 1774 - 1775
  • [12] Cancer Risks for MLH1 and MSH2 Mutation Carriers
    Dowty, James G.
    Win, Aung K.
    Buchanan, Daniel D.
    Lindor, Noralane M.
    Macrae, Finlay A.
    Clendenning, Mark
    Antill, Yoland C.
    Thibodeau, Stephen N.
    Casey, Graham
    Gallinger, Steve
    Le Marchand, Loic
    Newcomb, Polly A.
    Haile, Robert W.
    Young, Graeme P.
    James, Paul A.
    Giles, Graham G.
    Gunawardena, Shanaka R.
    Leggett, Barbara A.
    Gattas, Michael
    Boussioutas, Alex
    Ahnen, Dennis J.
    Baron, John A.
    Parry, Susan
    Goldblatt, Jack
    Young, Joanne P.
    Hopper, John L.
    Jenkins, Mark A.
    [J]. HUMAN MUTATION, 2013, 34 (03) : 490 - 497
  • [13] MSH2 and MLH1 immunodetection and the prognosis of colon cancer
    Perrin, J
    Monges, G
    Parriaux, D
    Noguchi, T
    Giovannini, MH
    Giovannini, M
    Delpero, JR
    Birnbaum, D
    Monges, G
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 19 (05) : 891 - 895
  • [14] Risks of cancer for MLH1 and MSH2 mutation carriers
    Dowty, James G.
    Win, Aung K.
    Buchanan, Daniel
    Thibodeau, Stephen N.
    Casey, Graham
    Lindor, Noralane M.
    Gallinger, Steve
    Le Marchand, Loic
    Haile, Robert
    Newcomb, Polly
    Hopper, John L.
    Jenkins, Mark A.
    [J]. GENETIC EPIDEMIOLOGY, 2009, 33 (08) : 811 - 811
  • [15] Expressional analysis of MLH1 and MSH2 in breast cancer
    Malik, Saima Shakil
    Masood, Nosheen
    Asif, Muhammad
    Ahmed, Parvez
    Shah, Zafar Ullah
    Khan, Jahangir Sarwar
    [J]. CURRENT PROBLEMS IN CANCER, 2019, 43 (02) : 97 - 105
  • [16] Prediction of MLH1 and MSH2 mutations in Lynch syndrome
    Balmana, Judith
    Stockwell, David H.
    Steyerberg, Ewout W.
    Stoffel, Elena M.
    Deffenbaugh, Amie M.
    Reid, Julia E.
    Ward, Brian
    Scholl, Thomas
    Hendrickson, Brant
    Tazelaar, John
    Burbidge, Lynn Anne
    Syngal, Sapna
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (12): : 1469 - 1478
  • [17] Tumours from MSH2 mutation carriers show loss of MSH2 expression but many tumours from MLH1 mutation carriers exhibit weak positive MLH1 staining
    Mangold, E
    Pagenstecher, C
    Friedl, W
    Fischer, HP
    Merkelbach-Bruse, S
    Ohlendorf, M
    Friedrichs, N
    Aretz, S
    Buettner, R
    Propping, P
    Mathiak, M
    [J]. JOURNAL OF PATHOLOGY, 2005, 207 (04): : 385 - 395
  • [18] Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer
    Chen, Y
    Wang, JS
    Fraig, MM
    Henderson, K
    Bissada, NK
    Watson, DK
    Schweinfest, CW
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 22 (05) : 1033 - 1043
  • [19] Immunohistochemical detection of MLH1 and MSH2 in renal cell tumors
    Lin, F
    Yang, XJ
    Brown, RE
    Zhang, PL
    [J]. LABORATORY INVESTIGATION, 2005, 85 : 153A - 153A
  • [20] Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma
    Stark, Andreas M.
    Doukas, Alexander
    Hugo, Heinz-Herrmann
    Hedderich, Juergen
    Hattermann, Kirsten
    Mehdorn, H. Maximilian
    Held-Feindt, Janka
    [J]. NEUROLOGICAL RESEARCH, 2015, 37 (02) : 95 - 105